Literature DB >> 20472307

Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients.

Masayuki Masuda1, Moe Matsumoto, Sachiko Tanaka, Kanako Nakajima, Nao Yamada, Nobuhiro Ido, Takao Ohtsuka, Masashi Nishida, Toshihiko Hirano, Hiroya Utsumi.   

Abstract

Myasthenia gravis (MG) is an autoimmune disorder generally mediated by antibodies against the acetylcholine receptors (AChR) of the skeletal muscles. CD4 T cells help B cells to produce antibodies through their production of cytokines or chemokines. In this study, we evaluated the frequency of regulatory (Treg) and IL-17 producing CD4 T-cell subsets (Th17) in peripheral blood mononuclear cells (PBMCs) of patients with MG. The transcription factor, forkhead transcription factor (Foxp3), is essential for T-cell regulatory function, and the orphan nuclear receptor, RORgammaT, is important in Th17 cell differentiation. In MG patients, Foxp3 mRNA expression in PBMCs was lower than those in healthy subjects (p=0.007), while there was no significant difference of RORgammaT mRNA expression between MG patients and healthy subjects. Glucocorticoid-induced tumour-necrosis-factor receptor-related protein (GITR) is expressed predominantly on CD4(+)CD25(+) Treg cells. We found that the number of GITR(+)CD4(+)CD25(+) T cells in peripheral lymphocytes in MG patients was lower than that in healthy subjects (P<0.01). In addition, there was a significant positive correlation between the change of the frequency of GITR(+)CD4(+)CD25(+) T cells and the changing rate in quantitative myasthenia gravis scores (%) (p=0.03). Furthermore, there was a significant negative correlation between the change of the percentage of GITR(+)CD4(+)CD25(+) T cells (% lymphocytes) and the changing rate of daily PSL doses (%) (P=0.002). The relative RORgammaT levels in PBMCs negatively correlated with the Th1/Th2 ratio in CD4(+) cells in MG patients (p=0.014). In conclusion, our findings suggest that Th17 cells affect the production of autoantibodies through their influence on the Th1- and Th2-cytokine balance in PBMCs of MG patients. On the other hand, Treg cells are suggested to be involved in the clinical condition or severity of MG disease. Copyright 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472307     DOI: 10.1016/j.jneuroim.2010.03.016

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  38 in total

Review 1.  Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.

Authors:  Jeffrey T Guptill; Madhu Soni; Matthew N Meriggioli
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

2.  Serum IL-21 levels decrease with glucocorticoid treatment in myasthenia gravis.

Authors:  Y Li; V K Rauniyar; W F Yin; B Hu; S Ouyang; B Xiao; H Yang
Journal:  Neurol Sci       Date:  2013-05-26       Impact factor: 3.307

3.  FoxP3(+) T regulatory cells in oral lichen planus and its correlation with the distinct clinical appearance of the lesions.

Authors:  Joabe S Pereira; Bárbara V Monteiro; Cassiano F Nonaka; Éricka J Silveira; Márcia C Miguel
Journal:  Int J Exp Pathol       Date:  2012-08       Impact factor: 1.925

Review 4.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

Review 5.  Regulatory T cells in the treatment of disease.

Authors:  Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

6.  Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients.

Authors:  Yingkai Li; Jeffrey T Guptill; Melissa A Russo; Janice M Massey; Vern C Juel; Lisa D Hobson-Webb; James F Howard; Manisha Chopra; Weibin Liu; John S Yi
Journal:  Exp Neurol       Date:  2018-11-22       Impact factor: 5.330

7.  Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants.

Authors:  Wen-Hua Xu; Ai-Mei Zhang; Ming-Shan Ren; Xu-Dong Zhang; Fang Wang; Xiu-Cai Xu; Qing Li; Jian Wang; Bang-Sheng Din; Yuan-Bo Wu; Gui-Hai Chen
Journal:  J Clin Immunol       Date:  2012-03-31       Impact factor: 8.317

Review 8.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

9.  Gene Polymorphisms for Both Auto-antigen and Immune-Modulating Proteins Are Associated with the Susceptibility of Autoimmune Myasthenia Gravis.

Authors:  Hai-Feng Li; Yu Hong; Xu Zhang; Yanchen Xie; Geir Olve Skeie; Hong-Jun Hao; Nils Erik Gilhus; Bing Liang; Yao-Xian Yue; Xian-Jun Zhang; Xiang Gao; Qi Wang; Zhe Gao; Xiao-Jun Ding; Min Song
Journal:  Mol Neurobiol       Date:  2016-08-08       Impact factor: 5.590

10.  Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Balaji Ganesh; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2012-10-07       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.